INBX

Insider Trades

Name	Value	Action	Price	Current Price
Viking Global Investors LP10 Percent Owner $10.0M308.6k shares SellOct 7, 2025 $32.25 --
Viking Global Investors LP10 Percent Owner $808k25k shares SellOct 7, 2025 $32.25 --
Viking Global Investors LP10 Percent Owner $526k16.3k shares SellOct 7, 2025 $32.25 --
Kayyem Jon FaizDirector $266k18.8k shares BuyNov 20, 2024 $14.19 --
Kayyem Jon FaizDirector $496k34.8k shares BuyNov 19, 2024 $14.23 --
Vuori Kristiina MDDirector $100k6.7k shares BuyOct 3, 2024 $15.00 --

News

prnewswire.comInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcomaprnewswire.comJun 15

prnewswire.comInhibrx Reports First Quarter 2026 Financial Resultsprnewswire.comMay 14

benzinga.comInhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Studybenzinga.comMay 11

marketbeat.comInhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Studymarketbeat.comMay 11

prnewswire.comInhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapyprnewswire.comMay 11

Trade INBX

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a biopharmaceutical company currently in its clinical development phase, focused on creating and advancing biological treatments for patients afflicted with severe, life-threatening medical conditions. Its pipeline features several investigational therapies, notably INBRX-109. This tetravalent therapeutic candidate, which targets death-receptor 5, is undergoing Phase 2 clinical trials for managing conventional chondrosarcoma that is either unresectable or has spread. Another significant asset is INBRX-106, a hexavalent sdAb-based candidate engineered to engage OX4, also in Phase 2 clinical evaluation. This drug aims to treat a broad spectrum of advanced cancers, including metastatic solid tumors, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA), renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was established in 2024 and is headquartered in La Jolla, California.

CEO: Mark Paul Lappe
IPO Date: Jun 4, 2024

Market Data

Open: $96.70
High: $99.33
Low: $91.18
Volume: 420.6K
Avg Volume: 434.5K
52W High: $155.29
52W Low: $13.97

Valuation

Market Cap: $1.4B
Enterprise Value: $1.2B
Dividend Yield: 85.0%

Financials

Free Cash Flow: $-130M
Revenue: $1.3M
Net Income: $-140M
Cash: $124M
Debt: $107M

Events

EarningsAug 12

EPS est. -2.28